Physician profile
Larry C Moore
NPI 1770553174
$9,285.91
in general payments reported to CMS, 2019-2025
37 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $402 · 2021: $1,206 · 2022: $1,244 · 2023: $2,119 · 2024: $2,137 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,729.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,623.89 | 2022-2025 | Biomonitor, Amvia Edge, Solia |
| Merck Sharp & Dohme LLC | $780.84 | 2021-2025 | Verquvo |
| Amgen INC. | $721.96 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $710.18 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $541.61 | 2020-2025 | |
| Cvrx, INC. | $540.91 | 2022-2025 | Barostim Neo System |
| Boston Scientific Corporation | $493.37 | 2019-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $452.25 | 2020-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $444.82 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $399.25 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $378.26 | 2019-2022 | |
| Pfizer INC. | $366.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.62 | 2019-2025 | Jardiance |
| Abbott Laboratories | $286.99 | 2019-2025 | Aveir, Mitraclip, Ensite |
| Scpharmaceuticals INC. | $244.70 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $167.55 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $158.60 | 2019-2023 | Xarelto |
| Cleerly, INC. | $135.60 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Lexicon Pharmaceuticals, INC. | $104.33 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $51.09 | 2024-2025 | |
| Shockwave Medical, INC | $41.05 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $38.57 | 2024 | Impella |
| Impulse Dynamics (USA) INC. | $33.12 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, Ltd. | $31.40 | 2021 | |
| Medtronic Vascular, INC. | $31.01 | 2020 | |
| Cardiovascular Systems INC. | $29.31 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.24 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $23.22 | 2022 | |
| Medtronic, INC. | $22.70 | 2022 | |
| Astellas Pharma US INC | $18.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.26 | 2019 | |
| Baxter Healthcare | $17.62 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Althera Pharmaceuticals LLC | $16.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.94 | 2021 | |
| Cordis US Corp. | $11.66 | 2022 | |
| Medicomp INC | $11.06 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $8.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.